前沿生物跌4.18% A股募20亿瑞银证券保荐上市

Group 1 - The stock of Frontier Biotech (688221.SH) closed at 14.89 yuan, with a decline of 4.18%, currently in a state of breaking issue [1] - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total shares post-issuance, at a price of 20.50 yuan per share [1] - The highest stock price recorded on the listing day was 35.53 yuan, marking the peak since its listing [1] Group 2 - The total amount raised by Frontier Biotech during the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan [1] - The company planned to use the raised funds for various projects, including the clinical research of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs (excluding VAT) for the initial public offering were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Group 3 - UBSAG, the sponsoring institution, participated in the strategic placement of the issuance, acquiring 2,926,829 shares, which is 3.25% of the total issuance, for an amount of approximately 60 million yuan [2] - The lock-up period for the shares acquired by UBSAG is 24 months, starting from the date of listing on the Shanghai Stock Exchange [2] Group 4 - The actual controller of Frontier Biotech is Dongxie (Xie Dong), who holds American nationality and has permanent residency in China [3] - In a simplified procedure for issuing shares to specific objects, Frontier Biotech issued 14,818,653 shares at a price of 13.51 yuan per share on September 22, 2022, raising a total of approximately 200.2 million yuan [3] - After deducting issuance costs, the net amount raised from this issuance was approximately 195.67 million yuan [3] Group 5 - The total fundraising from the two issuances by Frontier Biotech amounts to approximately 2.044 billion yuan [4]